Scopolamine Transdermal Patch Guidelines

Introduction to Scopolamine Transdermal Patch

• The National Comprehensive Cancer Network recommends that the onset of benefit for transdermal scopolamine patches is about 12 hours, making them inappropriate for imminently dying patients requiring secretion control 1
• The National Comprehensive Cancer Network suggests that scopolamine can be administered subcutaneously if more immediate effect is needed 1
• The American Academy of Otolaryngology-Head and Neck Surgery notes that in palliative care settings, scopolamine is often used to reduce excessive secretions associated with dyspnea, but its side effect profile and potential for significant toxicity must be carefully considered, especially when used for more than several days 3

Special Considerations

• The National Comprehensive Cancer Network recommends that scopolamine patches should be used with caution in elderly patients, patients with glaucoma, patients with urinary retention or prostatic hypertrophy, patients with seizure disorders, and pregnant women, due to increased risk of adverse effects 1
• The National Comprehensive Cancer Network also notes that scopolamine can be used subcutaneously for more immediate effect, particularly in patients who require rapid secretion control 2

Administration and Dosage

• The National Comprehensive Cancer Network states that the scopolamine patch is designed to deliver approximately 1 mg of scopolamine over 3 days, although this information is not directly cited 1
• However, it is cited that scopolamine can be administered subcutaneously if more immediate effect is needed 1